BACKGROUND: Elevations in blood pressure and visit-to-visit variability have been found to significantly increase the risk of cardiovascular morbidity and mortality in nondiabetic individuals. This study has assessed the association between all-cause mortality and blood pressure parameters [systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP), mean arterial pressure (MAP) and visit-to-visit variability] in patients with type 2 diabetes. MATERIALS AND METHODS: A longitudinal cohort study of 2161 patients with type 2 diabetes and a mean follow-up period of 66·7 ± 7·5 months. Using Cox regression models, blood pressure parameters were related to the risk of all-cause mortality. RESULTS: Visit-to-visit variability in SBP [HR: 1·048 (95% CI: 1·005-1·092; P = 0·03)], DBP [HR: 1·090 (95% CI: 1·021-1·163; P = 0·01)] and MAP [HR: 1·099 (95% CI: 1·033-1·170; P = 0·003)] significantly predicted all-cause mortality in patients with type 2 diabetes after adjusting for baseline data, mean follow-up blood pressure profiles and HbA1c. Visit-to-visit variability in PP [HR: 1·139 (95% CI: 1·030-1·258; P = 0·01)] significantly predicted cardiovascular mortality. Neither baseline nor follow-up SBP, DBP, PP nor MAP was significantly associated with all-cause and cardiovascular mortality after adjusting for blood pressure variability. The risk of all-cause mortality with a mean follow-up SBP has a U-shaped distribution. Patients with a mean follow-up DBP > 90 mmHg were at higher risk of mortality than those with DBP < 90 mmHg. CONCLUSIONS: Visit-to-visit variability in blood pressure was significantly associated with all-cause mortality independent of mean BP in patients with type 2 diabetes. The data for blood pressure variability might be regarded as a potentially important therapeutic target in the management of type 2 diabetes.
BACKGROUND: Elevations in blood pressure and visit-to-visit variability have been found to significantly increase the risk of cardiovascular morbidity and mortality in nondiabetic individuals. This study has assessed the association between all-cause mortality and blood pressure parameters [systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP), mean arterial pressure (MAP) and visit-to-visit variability] in patients with type 2 diabetes. MATERIALS AND METHODS: A longitudinal cohort study of 2161 patients with type 2 diabetes and a mean follow-up period of 66·7 ± 7·5 months. Using Cox regression models, blood pressure parameters were related to the risk of all-cause mortality. RESULTS: Visit-to-visit variability in SBP [HR: 1·048 (95% CI: 1·005-1·092; P = 0·03)], DBP [HR: 1·090 (95% CI: 1·021-1·163; P = 0·01)] and MAP [HR: 1·099 (95% CI: 1·033-1·170; P = 0·003)] significantly predicted all-cause mortality in patients with type 2 diabetes after adjusting for baseline data, mean follow-up blood pressure profiles and HbA1c. Visit-to-visit variability in PP [HR: 1·139 (95% CI: 1·030-1·258; P = 0·01)] significantly predicted cardiovascular mortality. Neither baseline nor follow-up SBP, DBP, PP nor MAP was significantly associated with all-cause and cardiovascular mortality after adjusting for blood pressure variability. The risk of all-cause mortality with a mean follow-up SBP has a U-shaped distribution. Patients with a mean follow-up DBP > 90 mmHg were at higher risk of mortality than those with DBP < 90 mmHg. CONCLUSIONS: Visit-to-visit variability in blood pressure was significantly associated with all-cause mortality independent of mean BP in patients with type 2 diabetes. The data for blood pressure variability might be regarded as a potentially important therapeutic target in the management of type 2 diabetes.
Authors: Keith M Diaz; Rikki M Tanner; Louise Falzon; Emily B Levitan; Kristi Reynolds; Daichi Shimbo; Paul Muntner Journal: Hypertension Date: 2014-07-28 Impact factor: 10.190
Authors: Iciar Martín-Timón; Cristina Sevillano-Collantes; Amparo Segura-Galindo; Francisco Javier Del Cañizo-Gómez Journal: World J Diabetes Date: 2014-08-15
Authors: Chenkai Wu; Michael G Shlipak; Robert S Stawski; Carmen A Peralta; Bruce M Psaty; Tamara B Harris; Suzanne Satterfield; Eric J Shiroma; Anne B Newman; Michelle C Odden Journal: Am J Hypertens Date: 2016-09-06 Impact factor: 2.689
Authors: Ankur Jindal; Mariana Garcia-Touza; Nidhi Jindal; Adam Whaley-Connell; James R Sowers Journal: Endocrinol Metab Clin North Am Date: 2013-08-01 Impact factor: 4.741
Authors: Daichi Shimbo; Steven Shea; Robyn L McClelland; Anthony J Viera; Devin Mann; Jonathan Newman; Joao Lima; Joseph F Polak; Bruce M Psaty; Paul Muntner Journal: Am J Hypertens Date: 2013-03-28 Impact factor: 2.689
Authors: Keith M Diaz; Paul Muntner; Emily B Levitan; Michael D Brown; Dianne M Babbitt; Daichi Shimbo Journal: J Hypertens Date: 2014-04 Impact factor: 4.844